Amarin boost­ed as an­oth­er mile­stone to the FDA’s big Vas­cepa de­ci­sion flies by with no sign of an Ad­Com

Amarin stock got a boost Wednes­day morn­ing as the com­pa­ny post­ed a nice spike in Vas­cepa sales for the lat­est quar­ter and com­pa­ny ex­ecs de­clared them­selves sat­is­fied now that an Ad­Com on Vas­cepa is “un­like­ly” ahead of a late Sep­tem­ber PDU­FA date.

In­vestors have been hold­ing their breath wait­ing to find out if the FDA will host an ex­pert pan­el re­view of Amarin’s sup­ple­men­tal NDA — look­ing to add the re­duc­tion in car­dio risks in­ves­ti­ga­tors re­port­ed from their RE­DUCE-IT study. In the mean­time, Amarin re­port­ed a 91% spike in sales for Q2 ’19 over Q2 ’18. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER